Mohamed-Eslam F Mohamed

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 31

Top Venues

Clinical and translational science

Clinical pharmacokinetics

Clinical pharmacology and therapeutics

Journal of clinical pharmacology

AbbVie

This page only lists publications with an associated author ORCID identifier.

Affiliation History

AbbVie

United States

Director :: Clinical Pharmacology and Pharmacometrics

University of Florida

United States

Post-Doctoral Fellow

Publications

Sumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, In-Ho Song, Peter Wung, Wei Liu, Mohamed-Eslam F Mohamed
Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis. Clinical and translational science 17 (2) (2024)
Sumit Bhatnagar, Louisa Schlachter, Doerthe Eckert, Sven Stodtmann, Wei Liu, Ana P Lacerda, Mohamed-Eslam F Mohamed
Pharmacokinetics and Exposure-Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease. Clinical pharmacology and therapeutics (2024)
Sumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, In-Ho Song, Peter Wung, Wei Liu, Mohamed-Eslam F Mohamed
Population pharmacokinetics and exposure-response analyses for efficacy and safety of apadacitinib in patients with axial Spondyloarthritis. Clinical and translational science 17 (2) (2024)
Mohamed-Eslam F Mohamed, Sandhya Girish, Rita Humeniuk, Silpa Nuthalapati, Amit Desai, Amita Datta-Mannan, Ferdous Gheyas, Jitendra Kanodia, Sravanthi Cheeti, Tong Zhu
Impact of COVID-19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective. Clinical pharmacology and therapeutics (2024)
Joan T Merrill, Yoshiya Tanaka, David D'Cruz, Karina Vila-Rivera, Daniel Siri, Xiaofeng Zeng, Amit Saxena, Martin Aringer, Kristin M D'Silva, Ling Cheng, Mohamed-Eslam F Mohamed, Lucia Siovitz, Sumit Bhatnagar, Marie-Claude Gaudreau, Thao T Doan, Alan Friedman
Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Sumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, In-Ho Song, Peter Wung, Wei Liu, Mohamed-Eslam F Mohamed
Population pharmacokinetics and exposure-response analyses for efficacy and safety of apadacitinib in patients with axial Spondyloarthritis. Clinical and translational science 17 (2) (2024)
Sumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, In-Ho Song, Peter Wung, Wei Liu, Mohamed-Eslam F Mohamed
Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis. Clinical and translational science 17 (2) (2024)
Mohamed-Eslam F Mohamed, Sandhya Girish, Rita Humeniuk, Silpa Nuthalapati, Amit Desai, Amita Datta-Mannan, Ferdous Gheyas, Jitendra Kanodia, Sravanthi Cheeti, Tong Zhu
Impact of COVID-19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective. Clinical pharmacology and therapeutics 116 (1) (2024)
Ryota Kikuchi, Yuli Qian, Mohamed Badawi, John P Savaryn, Shashikanth Gannu, Ann Eldred, Shuai Hao, Ahmed Hamed Salem, Wei Liu, Cheri E Klein, Mohamed-Eslam F Mohamed
Coproporphyrin-I as a Selective OATP1B Biomarker Can Be Used to Delineate the Mechanisms of Complex Drug-Drug Interactions: Cedirogant Case Study. Clinical pharmacology and therapeutics (2024)
Sumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, In-Ho Song, Peter Wung, Wei Liu, Mohamed-Eslam F Mohamed
Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis. Clinical and translational science 17 (2) (2024)
Joan T Merrill, Yoshiya Tanaka, David D'Cruz, Karina Vila-Rivera, Daniel Siri, Xiaofeng Zeng, Amit Saxena, Martin Aringer, Kristin M D'Silva, Ling Cheng, Mohamed-Eslam F Mohamed, Lucia Siovitz, Sumit Bhatnagar, Marie-Claude Gaudreau, Thao T Doan, Alan Friedman
Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Mohamed-Eslam F Mohamed, Yuli Qian, Ronilda R D'Cunha, Teresa Sligh, Laura K Ferris, Ann Eldred, Gweneth F Levy, Shuai Hao, Shashikanth Gannu, David G Rizzo, Wei Liu, Sasha Jazayeri, Howard Sofen, Roberto Carcereri De Prati
Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis. Clinical and translational science 17 (1) (2023)
Mohamed-Eslam F Mohamed, Yuli Qian, Ronilda R D'Cunha, Teresa Sligh, Laura K Ferris, Ann Eldred, Gweneth F Levy, Shuai Hao, Shashikanth Gannu, David G Rizzo, Wei Liu, Sasha Jazayeri, Howard Sofen, Roberto Carcereri De Prati
Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis. Clinical and translational science 17 (1) (2023)
Mohamed-Eslam F Mohamed, Yuli Qian, Ronilda R D'Cunha, Teresa Sligh, Laura K Ferris, Ann Eldred, Gweneth F Levy, Shuai Hao, Shashikanth Gannu, David G Rizzo, Wei Liu, Sasha Jazayeri, Howard Sofen, Roberto Carcereri De Prati
Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis. Clinical and translational science 17 (1) (2023)
Mohamed-Eslam F Mohamed, Sumit Bhatnagar, Julie M Parmentier, Priscila Nakasato, Peter Wung
Upadacitinib: Mechanism of action, clinical and translational science. Clinical and translational science (2023)
Mohamed-Eslam F Mohamed, Yuli Qian, Ronilda R D'Cunha, Teresa Sligh, Laura K Ferris, Ann Eldred, Gweneth F Levy, Shuai Hao, Shashikanth Gannu, David G Rizzo, Wei Liu, Sasha Jazayeri, Howard Sofen, Roberto Carcereri De Prati
Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis. Clinical and translational science 17 (1) (2023)
Mohamed-Eslam F Mohamed, Yuli Qian, Ronilda R D'Cunha, Teresa Sligh, Laura K Ferris, Ann Eldred, Gweneth F Levy, Shuai Hao, Shashikanth Gannu, David G Rizzo, Wei Liu, Sasha Jazayeri, Howard Sofen, Roberto Carcereri De Prati
Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis. Clinical and translational science (2023)
Zaid Temrikar, Elena Muensterman, Benjamin Engelhardt, Mohamed-Eslam F Mohamed
Use of Clinical Trial Simulations to Compare the Performance of Different Approaches for Population Analyses of Pediatric Pharmacokinetic Data. Journal of clinical pharmacology (2023)
Mohamed-Eslam F Mohamed, Yuli Qian, Ronilda R D'Cunha, Teresa Sligh, Laura K Ferris, Ann Eldred, Gweneth F Levy, Shuai Hao, Shashikanth Gannu, David G Rizzo, Wei Liu, Sasha Jazayeri, Howard Sofen, Roberto Carcereri De Prati
Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis. Clinical and translational science (2023)
Mohamed-Eslam F Mohamed, Yuli Qian, Ronilda R D'Cunha, Teresa Sligh, Laura K Ferris, Ann Eldred, Gweneth F Levy, Shuai Hao, Shashikanth Gannu, David G Rizzo, Wei Liu, Sasha Jazayeri, Howard Sofen, Roberto Carcereri De Prati
Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis. Clinical and translational science (2023)
Mohamed-Eslam F Mohamed, Yuli Qian, Ronilda R D'Cunha, Teresa Sligh, Laura K Ferris, Ann Eldred, Gweneth F Levy, Shuai Hao, Shashikanth Gannu, David G Rizzo, Wei Liu, Sasha Jazayeri, Howard Sofen, Roberto Carcereri De Prati
Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis. Clinical and translational science 17 (1) (2023)
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Doerthe Eckert, Wen Zhou, Wei Liu, Mohamed-Eslam F Mohamed
Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients. Clinical pharmacokinetics 62 (1) (2022)
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Doerthe Eckert, Wen Zhou, Wei Liu, Mohamed-Eslam F Mohamed
Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients. Clinical pharmacokinetics 62 (1) (2022)
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Doerthe Eckert, Wen Zhou, Wei Liu, Mohamed-Eslam F Mohamed
Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients. Clinical pharmacokinetics 62 (1) (2022)
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Doerthe Eckert, Wen Zhou, Wei Liu, Mohamed-Eslam F Mohamed
Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients. Clinical pharmacokinetics 62 (1) (2022)
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Doerthe Eckert, Wen Zhou, Wei Liu, Mohamed-Eslam F Mohamed
Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients. Clinical pharmacokinetics (2022)
Mohamed-Eslam F Mohamed, Insa Winzenborg, Ahmed A Othman, Patrick Marroum
Utility of Modeling and Simulation Approach to Support the Clinical Relevance of Dissolution Specifications: a Case Study from Upadacitinib Development. The AAPS journal 24 (2) (2022)
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Doerthe Eckert, Wen Zhou, Wei Liu, Mohamed-Eslam F Mohamed
Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients. Clinical pharmacokinetics 62 (1) (2022)
Abhishek G Sathe, Ahmed A Othman, Mohamed-Eslam F Mohamed
Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates. Journal of clinical pharmacology 61 (3) (2020)
Mohamed-Eslam F Mohamed, Sathej Gopalakrishnan, Henrique D Teixeira, Ahmed A Othman
Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses. Journal of clinical pharmacology 61 (5) (2020)
Mohamed-Eslam F Mohamed, Natella Rakhmanina, Hazem E Hassan
Inclusion of Adolescents With Adults in Phase 3 Clinical Trials: Overview of the Current State and a Call for Action. Journal of clinical pharmacology (2020)

Mohamed-Eslam F Mohamed.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Mohamed-Eslam F Mohamed